Moffitt logo
calledFromCancerPage=False - substr=
testProtocol=

Clinical Trials Search

Search Results:

Order By: 

Showing of 50

CLINICAL TRIAL 19117

A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19337

A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19603

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19646

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19776

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Disease Site: Any Site, Bones and Joints, Breast, Esophagus, Larynx, Lung, Other Respiratory and Intrathoracic Organs, Soft Tissue

View Trial Details

CLINICAL TRIAL 20030

A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node or T3N0 Positive Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 20089

A Phase 1b, Multicenter, Two-Part, Open label Study Of Trastuzumab Deruxtecan, An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)

Disease Site: Breast, Lung

View Trial Details

CLINICAL TRIAL 20132

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer

Disease Site: Any Site, Breast, Lip, Oral Cavity and Pharynx

View Trial Details

CLINICAL TRIAL 20159

A Phase 1 Study of ZW49 in Patients with Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Disease Site: Esophagus, Breast

View Trial Details

CLINICAL TRIAL 20487

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease

Disease Site: Brain and Nervous System, Breast, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 20897

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 20899

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Disease Site: Brain and Nervous System, Breast

View Trial Details

CLINICAL TRIAL 20902

A Phase I Trial of Capecitabine in Combination with Cemiplimab in Patients with Hormone Receptor Positive Metastatic Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 20964

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21163

A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21199

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21257

A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

Disease Site: Breast, Lung

View Trial Details

CLINICAL TRIAL 21587

A Dose-escalation Study of the Safety and Pharmacology of DAN 222 in Subjects with Metastatic Breast Cancer

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21609

A Phase I Dose Escalation And Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, And Anti-Tumor Activity Of PF-07260437 In Advanced Or Metastatic Solid Tumors

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21636

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Disease Site: Breast, Colon, Prostate, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21899

Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation

Disease Site: Breast, Other Female Genital, Ovary, Pancreas, Prostate

View Trial Details

CLINICAL TRIAL 21937

A Prospective, Multi-Center, Randomized, Double-Arm Trial to Determine the Impact of the SELENE System on Positive Margin Rates in Breast Conservation Surgery

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details

CLINICAL TRIAL 20479

Efficacy of SOAR (Survivors Overcoming and Achieving Resiliency) Survivorship Workshop for Breast Cancer Survivors

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 16933

Older Breast Cancer Patients: Risk For Cognitive Decline

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19209

Combined Imaging and Blood Biomarkers for Breast Cancer Diagnosis

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 20335

Physician Initiated Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21448

Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer

Disease Site: Breast, Brain metastasis

View Trial Details

CLINICAL TRIAL 21589

BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing

Disease Site: Breast, Colon, Esophagus, Lip, Oral Cavity and Pharynx, Lung, Ovary, Pancreas, Rectum, Stomach

View Trial Details

CLINICAL TRIAL 21610

The Influence of Psychosocial Factors on Opioid Decision-Making among Breast Cancer Survivors

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21760

Nutrition and Lifestyle Needs and Behaviors After Breast Cancer Diagnosis

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 19000

Evaluation of Anti-Her2 and Anti-Her3 T-Helper Response in Primary Breast Cancer

Disease Site: Breast - Female

View Trial Details

CLINICAL TRIAL 21164

Radiomics and Pathomics to Predict Upstaging of DCIS

Disease Site: Breast

View Trial Details

CLINICAL TRIAL 21452

Evaluating Gut Microbiome As A Biomarker Of Pathological Complete Response In Patients With Early Triple Negative Breast Cancer - A Pilot Study (TCC)

Disease Site: Breast

View Trial Details
;